Potential new treatment for diabetes and fatty liver disease

A study, published in the British Journal of Pharmacology, indicates a new molecule, which promotes the production of the FGF21 hormone, has anti-diabetic and anti-obesogenic effects that may be useful in developing treatments for non-alcoholic fatty liver disease and diabetes.

Science Daily

Subscribe to our email alerts